Pitney Bowes just delivered its strongest earnings quarter in years — and short sellers are not convinced.
Q1 2026 results, released after the close on May 5, beat on both lines. Adjusted EPS came in at $0.47, ahead of the $0.43 consensus. Revenue of $477.4 million beat the $471.8 million estimate. Net income more than doubled year-on-year to $58 million. Management reaffirmed full-year adjusted EPS guidance of $1.50–$1.65 against a Street estimate of $1.52, and reaffirmed revenue guidance of $1.80–$1.86 billion. On the call, CEO Kurt Wolf highlighted improving customer retention in SendTech, a Presort segment that is winning new business, and a bank division now in the midst of a second-stage strategic review. For a company that has traded like a restructuring story for years, this is a materially cleaner picture — and the stock has responded: up 41% over the past month to $15.54. Yet short interest, at nearly 12.7% of the free float, tells a very different story about what the market believes.
The positioning data points to a crowd that has been covering slowly but hasn't capitulated. Short interest was running above 23 million shares in late March. It has since pulled back to around 20.4 million — a decline of roughly 11% over the past month — but the pace of that covering has stalled this week, with SI edging up 3% over the past five sessions. That modest uptick after the earnings beat is notable: a clean quarter and a guidance reaffirmation would normally accelerate short covering, and the lack of urgency suggests a meaningful cohort of bears still believes the rally is overdone. Borrow conditions offer them no reason to panic. Cost to borrow is a modest 0.49% APR, down roughly 10% on the week and 11% over the past month — making it cheap to maintain short exposure. Availability in the lending market is wide, with no squeeze pressure evident. The ORTEX short score of 66 — elevated, but off the recent high of 70 seen two weeks ago — corroborates the picture: bears are cautious but not fleeing.
Options positioning adds nuance. The put/call ratio is running at 0.17, almost exactly in line with its 20-day average and a z-score barely above zero. That is an unusually call-heavy structure — reflecting the bullish positioning of recent weeks, as the stock ran into earnings — but the PCR is off its 52-week low of 0.15, touched in late April. Options traders are not piling in on the bull side any further, and are not yet rushing to hedge the post-earnings position. The setup looks balanced rather than euphoric.
The Street view is freshest from Citizens, the only active covering analyst. Citizens raised its price target to $17 on April 22 — its second consecutive raise after lifting from $13 to $14 just five days earlier — while maintaining a Market Outperform rating. At $17, that target sits above the current price of $15.54, suggesting the analyst sees further room. Truist Securities initiated coverage in December at Hold with an $11 target, and Goldman Sachs initiated at Neutral with an $11 target in November. Both of those targets are now deeply below where the stock trades; given the stock's 41% monthly rally, some recalibration from those two firms is likely but has not yet materialised. The dividend hike — from $0.09 to $0.10 per share — announced alongside Q1 results is another data point for the bull case, and Pitney Bowes scores in the 90th percentile on dividend scoring across the ORTEX universe. Against that, the EV/EBITDA multiple of 7.6x has re-rated alongside the price, and P/E now stands near 10x — reasonable for a stabilising franchise, but demanding relative to a business still shrinking revenues year-on-year. The bull case rests on SendTech stabilising and the bank division unlocking value; the bear case is that the structural mail volume decline reasserts itself and the recent quarterly outperformance proves one-off.
The institutional register offers one notable subplot. BlackRock added 1.9 million shares in the most recent reported period, taking its stake to just under 10% of shares outstanding. Hestia Capital Management — the activist investor on the board — trimmed 455,000 shares and also appeared in the insider trade log in April, selling small tranches in the $11 range. That selling by Hestia at prices well below the current level reads more as portfolio rebalancing after the run-up than outright conviction reversal. The General Counsel also sold small amounts through April at prices between $11.50 and $14.25. Neither is the kind of material cluster that would reframe the thesis, but it is worth noting that insiders and a key activist were net sellers into the very rally that has driven the stock to current levels.
What to watch next: the Q1 call flagged that second-stage strategic review advisers are being interviewed for the bank division, and management said growth is expected to return to the consolidated business in Q3. Those two timelines — the bank review outcome and the Q3 growth inflection — are the clearest binary events on the horizon, and whether short sellers use any post-earnings pullback to rebuild positions, or continue the slow cover, will be the tell on how credible the market finds the turnaround story.
See the live data behind this article on ORTEX.
Open PBI on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
